Details for New Drug Application (NDA): 009698
✉ Email this page to a colleague
NDA 009698 describes MILTOWN, which is a drug marketed by Medpointe Pharm Hlc and is included in two NDAs. Additional details are available on the MILTOWN profile page.
The generic ingredient in MILTOWN is meprobamate. There are twenty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the meprobamate profile page.
The generic ingredient in MILTOWN is meprobamate. There are twenty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the meprobamate profile page.
Summary for 009698
| Tradename: | MILTOWN |
| Applicant: | Medpointe Pharm Hlc |
| Ingredient: | meprobamate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 009698
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
